#United States #New York #Class Action #Investor Rights #Unicycive Therapeutics

Unicycive Therapeutics Class Action Notice

In a recent announcement, The Gross Law Firm has reached out to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY), urging those who have suffered financial losses to consider joining a class action lawsuit against the company. This follows numerous allegations about the company’s misrepresentation of its regulatory news and compliance status.

Background

Unicycive Therapeutics has been in the spotlight recently due to concerns regarding its product development and compliance with regulatory expectations. Specifically, investors are reported to have faced challenges concerning the oxylanthanum carbonate new drug application, a potential therapy that has not met expectations as initially projected. The alleged misstatements by the company have raised significant questions about the viability of its corporate business practices.

The class action period spans from March 29, 2024, to June 27, 2025, during which shareholders bought shares of UNCY. Allegations in the complaint include that defendants, comprising company executives, misled the market regarding the readiness and regulatory standing of their products. More specifically, the claims highlight that the company exaggerated its ability to meet FDA manufacturing compliance requirements.

Next Steps for Affected Shareholders

Shareholders who purchased stock during the rein period are encouraged to contact The Gross Law Firm to potentially become a lead plaintiff, although this step is not necessary to participate in recovering losses through the class action. Interested parties must register by October 14, 2025, to take part in the proceedings. Upon registration, participants will gain access to portfolio monitoring software, providing status updates throughout the case lifecycle.

It’s important for those affected not to delay their decision. Registering does not involve any cost or obligation, and allows investors to protect their rights in light of alleged wrongful conduct by the company.

Why Choose The Gross Law Firm?

The Gross Law Firm is nationally recognized for its commitment to holding companies accountable for their actions and ensuring investor rights are maintained. Their mission is to combat deceit and fraud in corporate practices, prompting the firm to seek recovery for investors impacted by misleading information that has led to unjust stock inflation. Past performance of the firm indicates a solid track record in this realm, although previous results don’t assure similar outcomes for future clients.

Contact Information

If you wish to pursue your rights as an affected shareholder, reach out to The Gross Law Firm for further details:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

The firm is dedicated to providing comprehensive support and ensuring that investors can regain control following potentially misleading claims made by the companies they engage with.

In conclusion, there has never been a better time for affected shareholders of Unicycive Therapeutics to act, as deadlines loom and participation in the class action could lead to possible compensation for losses experienced.